In early corporate news, AstraZeneca receives EU approval for a bladder cancer therapy, and a subdued housing market leaves MJ Gleeson eyeing adjusted pretax profit at the lower end of current market ...

AstraZeneca is reportedly considering moving its listing to the US. Here's why AZN's expected departure is alarming for the ...

Sky's James Sillars writes that a government, struggling for authority and prioritising economic growth, can not afford to ...

(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...

AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...

In turn, while the overall impact from them is still yet to be seen, Mr Bailey says tightening rates further could be more ...

The government must urgently abolish stamp duty on shares and abolish new cash ISAs to prevent the London Stock Exchange losing it’s most valuable listing, Astrazeneca, says Michael Healy The UK stock ...

AstraZeneca chief executive Sir Pascal Soriot is reportedly considering the move due to growing frustration with the UK's ...

London marked the slowest first half-year for IPO volume since 1997, a grim milestone punctuated by a report that AstraZeneca ...